Brief: First Tracks Biotherapeutics Announces Positive Top-Line Results For ANB033 In Gluten-Challenge Study In Celiac Disease
BRIEF-First Tracks Biotherapeutics Announces Positive Top-Line Results For ANB033 In Gluten-Challenge Study In Celiac Disease Oct 12 (Reuters) - First Tracks Biotherapeutics Inc TRAX.O:
FIRST TRACKS BIOTHERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FOR ANB033 IN GLUTEN-CHALLENGE STUDY IN CELIAC DISEASE
FIRST TRACKS BIOTHERAPEUTICS - ANB033 ACHIEVES STATISTICALLY SIGNIFICANT PROTECTIVE EFFECT IN CELIAC DISEASE PHASE 1B TRIAL
FIRST TRACKS BIOTHERAPEUTICS - ANB033 WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED TO DATE
FIRST TRACKS BIOTHERAPEUTICS - COHORT 2 OF ANB033 PHASE 1B TRIAL IN CELIAC DISEASE TOP-LINE DATA EXPECTED Q1 2027
FIRST TRACKS BIOTHERAPEUTICS - ANB033 PHASE 1B COHORT IN EOSINOPHILIC ESOPHAGITIS TOP-LINE DATA EXPECTED Q3 2027
FIRST TRACKS BIOTHERAPEUTICS - ANB033 SHOWS +0.49 PLACEBO-ADJUSTED DELTA IN VH:CD RATIO (P=0.009) AT WEEK 6
FIRST TRACKS BIOTHERAPEUTICS - ANB033 PHASE 2 DEVELOPMENT IN VITILIGO AND ADDITIONAL INDICATION TO INITIATE IN H1 2027
Source text: ID:nGNX6RxXp
Further company coverage: TRAX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on First Tracks Biotherapeutics
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
First Tracks Biotherapeutics up after $200 mln equity raise
Health Rounds: New drug treats gluten-caused intestinal damage in celiac patients
US RESEARCH ROUNDUP-Essex Property Trust, Qualys, Vulcan Materials